Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain

Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an...

Full description

Bibliographic Details
Main Authors: Young-Hwan Jung, Yeo Ok Kim, Koon Mook Kang, Hyung Gon Lee, Borum Son, Xuehao Han, Eunseok Oh, Siwon Kim, Seon Hee Seo, Jong-Hyun Park, Ki Duk Park, Woong Mo Kim, Myung Ha Yoon, Yong-Chul Kim
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/15/4/407
_version_ 1797434328750227456
author Young-Hwan Jung
Yeo Ok Kim
Koon Mook Kang
Hyung Gon Lee
Borum Son
Xuehao Han
Eunseok Oh
Siwon Kim
Seon Hee Seo
Jong-Hyun Park
Ki Duk Park
Woong Mo Kim
Myung Ha Yoon
Yong-Chul Kim
author_facet Young-Hwan Jung
Yeo Ok Kim
Koon Mook Kang
Hyung Gon Lee
Borum Son
Xuehao Han
Eunseok Oh
Siwon Kim
Seon Hee Seo
Jong-Hyun Park
Ki Duk Park
Woong Mo Kim
Myung Ha Yoon
Yong-Chul Kim
author_sort Young-Hwan Jung
collection DOAJ
description Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, <b>17</b>, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC<sub>50</sub> values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound <b>17</b> showed partial agonism (EC<sub>50</sub> = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound <b>17</b> showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain.
first_indexed 2024-03-09T10:31:38Z
format Article
id doaj.art-f336e7f773a0407694da045b1a934c52
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-03-09T10:31:38Z
publishDate 2022-03-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-f336e7f773a0407694da045b1a934c522023-12-01T21:18:02ZengMDPI AGPharmaceuticals1424-82472022-03-0115440710.3390/ph15040407Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic PainYoung-Hwan Jung0Yeo Ok Kim1Koon Mook Kang2Hyung Gon Lee3Borum Son4Xuehao Han5Eunseok Oh6Siwon Kim7Seon Hee Seo8Jong-Hyun Park9Ki Duk Park10Woong Mo Kim11Myung Ha Yoon12Yong-Chul Kim13School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, KoreaDepartment of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, KoreaSchool of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, KoreaDepartment of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, KoreaSchool of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, KoreaDepartment of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, KoreaDepartment of Chemistry, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, KoreaConvergence Research Center for Brain Science, Korea Institute of Science and Technology (KIST), Seoul 02792, KoreaConvergence Research Center for Brain Science, Korea Institute of Science and Technology (KIST), Seoul 02792, KoreaConvergence Research Center for Brain Science, Korea Institute of Science and Technology (KIST), Seoul 02792, KoreaConvergence Research Center for Brain Science, Korea Institute of Science and Technology (KIST), Seoul 02792, KoreaDepartment of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, KoreaDepartment of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, KoreaSchool of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, KoreaNeuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, <b>17</b>, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC<sub>50</sub> values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound <b>17</b> showed partial agonism (EC<sub>50</sub> = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound <b>17</b> showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain.https://www.mdpi.com/1424-8247/15/4/407neuropathic painmultifunctional compoundmultiple mechanisms of actiontianeptineopioid receptorneurotransmitter transporter
spellingShingle Young-Hwan Jung
Yeo Ok Kim
Koon Mook Kang
Hyung Gon Lee
Borum Son
Xuehao Han
Eunseok Oh
Siwon Kim
Seon Hee Seo
Jong-Hyun Park
Ki Duk Park
Woong Mo Kim
Myung Ha Yoon
Yong-Chul Kim
Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
Pharmaceuticals
neuropathic pain
multifunctional compound
multiple mechanisms of action
tianeptine
opioid receptor
neurotransmitter transporter
title Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_full Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_fullStr Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_full_unstemmed Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_short Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_sort development of dibenzothiazepine derivatives as multifunctional compounds for neuropathic pain
topic neuropathic pain
multifunctional compound
multiple mechanisms of action
tianeptine
opioid receptor
neurotransmitter transporter
url https://www.mdpi.com/1424-8247/15/4/407
work_keys_str_mv AT younghwanjung developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT yeookkim developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT koonmookkang developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT hyunggonlee developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT borumson developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT xuehaohan developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT eunseokoh developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT siwonkim developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT seonheeseo developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT jonghyunpark developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kidukpark developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT woongmokim developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT myunghayoon developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT yongchulkim developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain